Member News

Connecticut Innovations (CI), the state’s quasi-public authority responsible for technology-based innovation and economic development, today announced that it has made a follow-on investment of $269,160 in antibiotics developer BioRelix Inc. (BioRelix) of New Haven, Conn., through its Eli Whitney Fund. This investment will be part of a funding round of approximately $2.5 million for the company. CI made its first investment of $500,000 in BioRelix in December 2011. BioRelix i

Antibiotics developer utilizes novel riboswitch-based drug discovery platform Connecticut Innovations (CI), the state’s quasi-public authority responsible for technology-based economic development, today announced that it has made an investment of $500,000 in antibiotics developer BioRelix Inc. (BioRelix) of New Haven, Conn., through its Eli Whitney Fund. This investment is part of a $4.244 million round of funding for the company. BioRelix is developing antibiotics using a n